🇺🇸 FDA
Pipeline program

Randomized: 40 mg Paltusotine

CRN00808-11

Phase 2 small_molecule completed

Quick answer

Randomized: 40 mg Paltusotine for Carcinoid Syndrome is a Phase 2 program (small_molecule) at Crinetics Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Crinetics Pharmaceuticals
Indication
Carcinoid Syndrome
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials